Crystalys Therapeutics
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
$130MSeries B
Role not disclosedFL
Frazier Life Sciences
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Enterprise software · Jan 1, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $245M 2 disclosed · full round size, not this investor’s share